Toll-Like Receptor 4 in Acute Respiratory Distress Syndrome: Good Time to Target?
Journal of Cellular & Molecular Anesthesia,
Vol. 5 No. 4 (2020),
Acute respiratory distress syndrome (ARDS) is considered a major cause of death in the world. ARDS is defined by life-threatening pulmonary edema and hypoxemia with a mortality rate of up to 40%. Recent advances in understating cellular aspects of the syndrome have shed light on possible new treatments and reduction of mortality. Toll-like receptors (TLRs) are pattern recognition receptors (PRRs) involved in adaptive and innate immunity. They are present in the alveoli and their activation can lead to inflammatory responses and finally acute lung injury. Among them, Toll-like receptor 4 (TLR4) is abundantly available on the epithelial cells of the alveoli and also on resident monocytes. TLR4 is one of the players that can promote alveolar damages during ARDS. Here, we focus on the TLR4 role in ARDS pathophysiology. We also present the potential therapies for the syndrome based on TLR4 inhibition.
- Toll-like receptor4
How to Cite
Force ADT, Ranieri VM, Rubenfeld GD, Thompson BT, Ferguson ND, Caldwell E. Acute respiratory distress syndrome. JAMA. 2012;307(23):2526-33.
Faritous ZS, Aghdaie N, Yazdanian F, Azarfarin R, Dabbagh A. Perioperative risk factors for prolonged mechanical ventilation and tracheostomy in women undergoing coronary artery bypass graft with cardiopulmonary bypass. Saudi J Anaesth. 2011;5(2):167-9.
Takeda K, Akira S. Roles of Toll‐like receptors in innate immune responses. Genes to Cells. 2001;6(9):733-742.
Akira S, Takeda K, Kaisho T. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol. 2001;2(8):675-80.
Tsan M, Gao B. Endogenous ligands of Toll‐like receptors. J Leukoc Biol. 2004;76(3):514-9.
Takeda K, Akira S. Toll-like receptors in innate immunity. Int Immunol. 2005;17(1):1-14.
Medzhitov R. Toll-like receptors and innate immunity. Nat Rev Immunol. 2001;1(2):135-45.
Ohashi K, Burkart V, Flohé S, Kolb H. Cutting edge: heat shock protein 60 is a putative endogenous ligand of the toll-like receptor-4 complex. J Immunol. 2000;164(2):558-61.
Pålsson‐McDermott EM, O’Neill LAJ. Signal transduction by the lipopolysaccharide receptor, Toll‐like receptor‐4. Immunology. 2004;113(2):153-62.
Saadat H, Ziai SA, Ghanemnia M, Namazi MH, Safi M, Vakili H, et al. Opium Addiction Increases Interleukin 1 Receptor Antagonist (IL-1Ra) in the Coronary Artery Disease Patients. PLoS One. 2012;7(9):e44939
Barton GM, Medzhitov R. Toll-like receptor signaling pathways. Science (80- ). 2003;300(5625):1524-5.
Bagheri B, Sohrabi B, Movassaghpur A, et al. Monocyte expression of Toll-like receptor-4 in patients with stable angina undergoing percutaneous coronary intervention. Iran J Immunol. 2012;9(3).
Zali H, Golchin A, Farahani M, Yazdani M, Ranjbar MM, Dabbagh A. FDA Approved Drugs Repurposing of Toll-Like Receptor4 (TLR4) Candidate for Neuropathy. Iran J Pharm Res. 2019;18(3):1639-47.
Bagheri B, Razavi SS, Gohari A, Salarian S, Dabbagh A. Toll-Like Receptor 4 in Ventilator-Induced Lung Injuries. J Cell Mol Anesth. 2015;1(1):34-9.
Mendez JL, Hubmayr RD. New insights into the pathology of acute respiratory failure. Curr Opin Crit Care. 2005;11(1):29-36.
Cardinal-Fernandez P, Ortiz G, Chang C-H, et al. Predicting the impact of diffuse alveolar damage through open lung biopsy in acute respiratory distress syndrome—The PREDATOR study. J Clin Med. 2019;8(6):829.
Ware LB, Matthay MA. The acute respiratory distress syndrome. N Engl J Med. 2000;342(18):1334-49.
Yang XQ, Murani E, Ponsuksili S, Wimmers K. Association of TLR4 polymorphism with cytokine expression level and pulmonary lesion score in pigs. Mol Biol Rep. 2012;39(6):7003-9.
Ozretić P, da Silva Filho MI, Catalano C, et al. Association of NLRP1 Coding Polymorphism with Lung Function and Serum IL-1β Concentration in Patients Diagnosed with Chronic Obstructive Pulmonary Disease (COPD). Genes (Basel). 2019;10(10):783.
Deng Y, Yang Z, Gao Y, et al. Toll-like receptor 4 mediates acute lung injury induced by high mobility group box-1. PLoS One. 2013;8(5):e64375.
Ding X, Jin S, Tong Y, et al. TLR4 signaling induces TLR3 up-regulation in alveolar macrophages during acute lung injury. Sci Rep. 2017;7:34278.
Jiang K, Guo S, Zhang T, et al. Downregulation of TLR4 by miR-181a provides negative feedback regulation to lipopolysaccharide-induced inflammation. Front Pharmacol. 2018;9:142.
Ye R, Liu Z. ACE2 exhibits protective effects against LPS-induced acute lung injury in mice by inhibiting the LPS-TLR4 pathway. Exp Mol Pathol. 2020;113:104350.
Go H, Koh J, Kim HS, Jeon YK, Chung DH. Expression of toll-like receptor 2 and 4 is increased in the respiratory epithelial cells of chronic idiopathic interstitial pneumonia patients. Respir Med. 2014;108(5):783-92.
Yang H-Z, Wang J-P, Mi S, et al. TLR4 activity is required in the resolution of pulmonary inflammation and fibrosis after acute and chronic lung injury. Am J Pathol. 2012;180(1):275-92.
Li G, Liu D, Zhang Y, et al. Celastrol inhibits lipopolysaccharide-stimulated rheumatoid fibroblast-like synoviocyte invasion through suppression of TLR4/NF-κB-mediated matrix metalloproteinase-9 expression. PLoS One. 2013;8(7):e68905.
Wang J, Lu J, Lan Y, Zhou H, Li W, Xiang M. Total coumarins from Urtica dentata Hand prevent murine autoimmune diabetes via suppression of the TLR4-signaling pathways. J Ethnopharmacol. 2013;146(1):379-92.
Ungaro R, Fukata M, Hsu D, et al. A novel Toll-like receptor 4 antagonist antibody ameliorates inflammation but impairs mucosal healing in murine colitis. Am J Physiol Liver Physiol. 2009;296(6):1167-79.
Roger T, Froidevaux C, Le Roy D, et al. Protection from lethal gram-negative bacterial sepsis by targeting Toll-like receptor 4. Proc Natl Acad Sci. 2009;106(7):2348-52.
DeVry CG, Valdez M, Gao L, et al. RDP58, a novel immunomodulatory peptide, ameliorates clinical signs of disease in the Lewis rat model of acute experimental autoimmune encephalomyelitis. J Neuroimmunol. 2004;152(1-2):33-43.
Yu X, Song B, Huang C, et al. Prolonged survival time of allografts by the oral administration of RDP58 linked to the cholera toxin B subunit. Transpl Immunol. 2012;27(2-3):122-7.
Ii M, Matsunaga N, Hazeki K, et al. A novel cyclohexene derivative, ethyl (6R)-6-(N-(2-Chloro-4-fluorophenyl) sulfamoyl) cyclohex-1-ene-1-carboxylate (TAK-242), selectively inhibits toll-like receptor 4-mediated cytokine production through suppression of intracellular signaling. Mol Pharmacol. 2006;69(4):1288-95.
Rice TW, Wheeler AP, Bernard GR, et al. A randomized, double-blind, placebo-controlled trial of TAK-242 for the treatment of severe sepsis. Crit Care Med. 2010;38(8):1685-94.
Plunk MA, Alaniz A, Olademehin OP, Ellington TL, Shuford KL, Kane RR. Design and Catalyzed Activation of Tak-242 Prodrugs for Localized Inhibition of TLR4-Induced Inflammation. ACS Med Chem Lett. 2020;11(2):141-6.
Zheng L, Zhu Q, Xu C, et al. Glycyrrhizin mitigates radiation‐induced acute lung injury by inhibiting the HMGB1/TLR4 signaling pathway. J Cell Mol Med. 2020;24(1):214-26.
Liu T, Zhao L, Chen S, et al. Polygonatum sibiricum polysaccharides prevent LPS‑induced acute lung injury by inhibiting inflammation via the TLR4/Myd88/NF‑κB pathway. Exp Ther Med. 2020;20(4):3733-9.
Peng L-Y, Shi H-T, Yuan M, et al. Madecassoside Protects Against LPS-Induced Acute Lung Injury via Inhibiting TLR4/NF-κB Activation and Blood-Air Barrier Permeability. Front Pharmacol. 2020;11:807.
Wu H, Yang Y, Guo S, et al. Nuciferine ameliorates inflammatory responses by inhibiting the TLR4-mediated pathway in lipopolysaccharide-induced acute lung injury. Front Pharmacol. 2017;8:939.
Wang Y, Wu Y, Zhang J, et al. Ruscogenin attenuates particulate matter-induced acute lung injury in mice via protecting pulmonary endothelial barrier and inhibiting TLR4 signaling pathway. Acta Pharmacol Sin. 2020:1-9.
Gao W, Xiong Y, Li Q, Yang H. Inhibition of toll-like receptor signaling as a promising therapy for inflammatory diseases: a journey from molecular to nano therapeutics. Front Physiol. 2017;8:508.
Xue B-B, Chen B-H, Tang Y-N, Weng C-W, Lin L-N. Dexmedetomidine protects against lung injury induced by limb ischemia-reperfusion via the TLR4/MyD88/NF-κB pathway. Kaohsiung J Med Sci. 2019;35(11):672-8.
- Abstract Viewed: 114 times
- PDF Downloaded: 121 times